These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6306206)

  • 21. Determination of the new anticancer agent KW 2149, 7-N-[2-[2-(gamma-L-glutamylamino)ethyl)dithio)ethyl]mitomycin C, an analogue of mitomycin C.
    Pattyn G; van Oosterom AT; de Bruijn EA; Tjaden UR
    J Chromatogr; 1991 Mar; 564(1):352-4. PubMed ID: 1860933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of mitomycin C in rabbit and human.
    van Hazel GA; Kovach JS
    Cancer Chemother Pharmacol; 1982; 8(2):189-92. PubMed ID: 6809356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies on the mechanism of resistance to mitomycin C and porfiromycin in a human cell strain derived from a cancer-prone individual.
    Marshall RS; Paterson MC; Rauth AM
    Biochem Pharmacol; 1991 May; 41(9):1351-60. PubMed ID: 1902110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells.
    Marshall RS; Rauth AM
    Cancer Res; 1988 Oct; 48(20):5655-9. PubMed ID: 3167822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
    Iyengar BS; Sami SM; Remers WA; Bradner WT; Schurig JE
    J Med Chem; 1983 Jan; 26(1):16-20. PubMed ID: 6827524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decomposition of mitomycin and anthracycline cytostatics in cell culture media.
    Beijnen JH; Van der Nat JM; Labadie RP; Underberg WJ
    Anticancer Res; 1986; 6(1):39-43. PubMed ID: 3082277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of influence of the carbamoyl group on the stereochemistry of the acid-catalyzed opening of the aziridine ring of the mitomycins and of congeners.
    Hornemann U; Keller PJ; Takeda K
    J Med Chem; 1985 Jan; 28(1):31-6. PubMed ID: 3965712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival of hematopoietic and leukemic colony-forming cells in vivo after administration of mitomycin C or porfiromycin.
    Razek A; Valeriote F; Vietti T
    J Natl Cancer Inst; 1973 Dec; 51(6):1845-8. PubMed ID: 4765389
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of the superoxide dismutase inhibitor, diethyldithiocarbamate, on the cytotoxicity of mitomycin antibiotics.
    Pritsos CA; Keyes SR; Sartorelli AC
    Cancer Biochem Biophys; 1989 Oct; 10(4):289-98. PubMed ID: 2559790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of mitomycin C in serum by high-performance liquid chromatography with dual-electrode coulometric detection.
    Ohkubo T; Nambara T
    J Chromatogr; 1990 May; 527(2):441-6. PubMed ID: 2117616
    [No Abstract]   [Full Text] [Related]  

  • 31. Stereoselectivity in the mechanism of acid hydrolysis of mitomycins.
    Underberg WJ; Beijnen JH
    Chem Pharm Bull (Tokyo); 1987 Nov; 35(11):4557-61. PubMed ID: 3442889
    [No Abstract]   [Full Text] [Related]  

  • 32. Studies related to antitumor antibiotics. Part XIV. Reactions of mitomycin B with DNA.
    Lown JW; Weir G
    Can J Biochem; 1978 May; 56(5):269-304. PubMed ID: 27289
    [No Abstract]   [Full Text] [Related]  

  • 33. PHENETHYL ALCOHOL SYNERGISM WITH MITOMYCIN C, PORFIROMYCIN, AND STREPTONIGRIN.
    WHITE JR; WHITE HL
    Science; 1964 Sep; 145(3638):1312-3. PubMed ID: 14173417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specificity of antisera produced against mitomycin C.
    Fujiwara K; Saikusa H; Kitagawa T; Takahashi S; Konishi Y
    Cancer Treat Rep; 1983 Dec; 67(12):1079-84. PubMed ID: 6418380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of mitomycin C and porfiromycin on exponentially growing and plateau phase cultures.
    Rockwell S; Hughes CS
    Cell Prolif; 1994 Mar; 27(3):153-63. PubMed ID: 10465006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck.
    Haffty BG; Son YH; Wilson LD; Papac R; Fischer D; Rockwell S; Sartorelli AC; Ross D; Sasaki CT; Fischer JJ
    Radiat Oncol Investig; 1997; 5(5):235-45. PubMed ID: 9372546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of transport and intracellular binding of porfiromycin in HCT 116 human colon carcinoma cells.
    Pan SS; Johnson R; Gonzalez H; Thohan V
    Cancer Res; 1989 Sep; 49(18):5048-53. PubMed ID: 2766276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies on curcumin and curcuminoids. VI. Kinetics of curcumin degradation in aqueous solution.
    Tønnesen HH; Karlsen J
    Z Lebensm Unters Forsch; 1985 May; 180(5):402-4. PubMed ID: 4013525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of pH on DNA alkylation by enzyme-activated mitomycin C and porfiromycin.
    Yu F; Pan SS
    Mol Pharmacol; 1993 Jun; 43(6):863-9. PubMed ID: 8391116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and application of a sensitive enzyme immunoassay for 7-N-(p-hydroxyphenyl)mitomycin C.
    Fujiwara K; Nakamura H; Kitagawa T; Nakamura N; Saito A; Hara K
    Cancer Res; 1984 Sep; 44(9):4172-6. PubMed ID: 6430558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.